ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Amgen, Otsuka and Simcere Pharmaceutical Group side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Amgen×Otsuka×Simcere Pharmaceutical Group×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AmgenOtsukaSimcere Pharmaceutical Group
studies on the registry1,08878482
open to participants now505615
phase 3 studies under way50315
reach primary completion within a year35236
programswith a study of their own in two years242516

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAmgenOtsukaSimcere Pharmaceutical Group
Phase 1

Amgen: 8 of its 24 programs at phase 1

  1. AMG 691phase 1
  2. AMG 127phase 1
  3. etakafusp alfaphase 1
  4. Pan-KRAS Inhibitor AMG 410phase 1
  5. tambotatug pelitecanphase 1

and 3 more — sign in to see them all

33%

Otsuka: 12 of its 25 programs at phase 1

  1. VIS171phase 1
  2. 1-(12-(1 CARBOXYCYCLOPROPYL)DODECYL)CYCLOPROPANE-1-CARBOXYLIC acidphase 1
  3. ARC-02phase 1
  4. HBM7020phase 1
  5. SEP-380135phase 1

and 7 more — sign in to see them all

48%

Simcere Pharmaceutical Group: 9 of its 16 programs at phase 1

  1. dose expansion of SIM0609 in GC/GEJC cohortphase 1
  2. SIM0388phase 1
  3. SIM0518phase 1
  4. SIM0532phase 1
  5. SIM0609phase 1

and 4 more — sign in to see them all

56%
Phase 2

Amgen: 1 of its 24 programs at phase 2

  1. AMG 732phase 2
4%

Otsuka: 2 of its 25 programs at phase 2

  1. VIS954phase 2
  2. OPC 131461phase 2
8%

Simcere Pharmaceutical Group: 1 of its 16 programs at phase 2

  1. SIM0278phase 2
6%
Phase 3

Amgen: 7 of its 24 programs at phase 3

  1. maridebart cafraglutidephase 3
  2. tarlatamabphase 3
  3. xaluritamigphase 3
  4. sotorasibphase 3
  5. olpasiranphase 3

and 2 more — sign in to see them all

29%

Otsuka: 10 of its 25 programs at phase 3

  1. sibeprenlimabphase 3
  2. ulotarontphase 3
  3. centanafadine hydrochloridephase 3
  4. futibatinibphase 3
  5. repinatrabitphase 3

and 5 more — sign in to see them all

40%

Simcere Pharmaceutical Group: 5 of its 16 programs at phase 3

  1. SIM0270phase 3
  2. suvemcitugphase 3
  3. SIM0811phase 3
  4. tipiracilphase 3
  5. Trifluridinephase 3
31%
Approved, new studies

Amgen: 8 of its 24 programs at approved, new studies

  1. inebilizumabapproved, new study
  2. blinatumomabapproved, new study
  3. apremilastapproved, new study
  4. evolocumabapproved, new study
  5. romiplostimapproved, new study

and 3 more — sign in to see them all

33%

Otsuka: 1 of its 25 programs at approved, new studies

  1. Tolvaptanapproved, new study
4%

Simcere Pharmaceutical Group: 1 of its 16 programs at approved, new studies

  1. trilaciclibapproved, new study
6%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Amgen12 readouts · 3 phase 3·

Amgen, Dec ’26: 1 program whose next study reaches primary completion

  1. sotorasibphase 3 · Dec 17 · NCT04185883

Amgen, Jan ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. AMG 732phase 2 · Jan 6 · NCT06401044
  2. apremilastapproved, new study · Jan 10 · NCT07908641
  3. romosozumabapproved, new study · Jan 14 · NCT07811999
  4. maridebart cafraglutidephase 3 · Jan 21 · NCT06858839

Amgen, Feb ’27: 1 program whose next study reaches primary completion

  1. xaluritamigphase 3 · Feb 17 · NCT06613100

Amgen, Mar ’27: 1 program whose next study reaches primary completion

  1. AMG 691phase 1 · Mar 17 · NCT07745907

Amgen, Apr ’27: 2 programs whose next study reaches primary completion

  1. inebilizumabapproved, new study · Apr 13 · NCT05549258
  2. tarlatamabphase 3 · Apr 24 · NCT06598306

Amgen, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. evolocumabapproved, new study · May 29 · NCT05284747
·

Amgen, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. afliberceptphase 3 · Jul 31 · NCT07614776
··

Amgen, Oct ’27: 1 program whose next study reaches primary completion

  1. AMG 127phase 1 · Oct 2 · NCT07590193
Otsuka8 readouts · 3 phase 3·

Otsuka, Dec ’26: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. difamilastphase 3 · Dec 0 · NCT07173478
  2. futibatinibphase 3 · Dec 0 · NCT05727176
·

Otsuka, Feb ’27: 1 program whose next study reaches primary completion

  1. repinatrabitphase 3 · Feb 9 · NCT07713758

Otsuka, Mar ’27: 1 program whose next study reaches primary completion

  1. sibeprenlimabphase 3 · Mar 13 · NCT06928142
·

Otsuka, May ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. centanafadine hydrochloridephase 3 · May 27 · NCT07759154
  2. zipalertinibphase 3 · May 27 · NCT05973773

Otsuka, Jun ’27: 1 program whose next study reaches primary completion

  1. zimberelimabphase 3 · Jun 0 · NCT04999761
·

Otsuka, Aug ’27: 1 program whose next study reaches primary completion

  1. 1-(12-(1 CARBOXYCYCLOPROPYL)DODECYL)CYCLOPROPANE-1-CARBOXYLIC acidphase 1 · Aug 25 · NCT07525960
··
Simcere Pharmaceutical Group2 readouts · 1 phase 3·······

Simcere Pharmaceutical Group, Jun ’27: 1 program whose next study reaches primary completion

  1. SIM0388phase 1 · Jun 0 · NCT07007988

Simcere Pharmaceutical Group, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. trilaciclibapproved, new study · Jul 15 · NCT07881705
···
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Amgen

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 5

Otsuka

New programs 0

None

Reached a new phase 1

  • VIS954phase 2 · Oct 23 · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Study stopped 1

  • SEP-380135phase 1 · withdrawn Nov 19 · none of its studies left running“The trial was withdrawn prior to participant enrollment.” · NCT07455084

Primary completion later 3

Simcere Pharmaceutical Group

New programs 1

  • SIM0518phase 1 · first study · Oct 22 · Carcinoma, Non-Small-Cell Lung

Reached a new phase 1

  • SIM0811phase 3 · Oct 23 · Ischemic Stroke

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 10 in all. A program counts in each condition its studies name most.

ConditionAmgenOtsukaSimcere Pharmaceutical Group
Carcinoma, Non-Small-Cell Lungall three · compare here

Amgen in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. sotorasibphase 3
  2. Pan-KRAS Inhibitor AMG 410phase 1
  3. tambotatug pelitecanphase 1
  4. romiplostimapproved, new study

Their studies: Amgen’s studies of Carcinoma, Non-Small-Cell Lung in search

Otsuka in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. zipalertinibphase 3
  2. zimberelimabphase 3

Their studies: Otsuka’s studies of Carcinoma, Non-Small-Cell Lung in search

Simcere Pharmaceutical Group in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. SIM0518phase 1
  2. trilaciclibapproved, new study

Their studies: Simcere Pharmaceutical Group’s studies of Carcinoma, Non-Small-Cell Lung in search

Colorectal Neoplasms2 of 3 · compare here

Amgen in Colorectal Neoplasms: 2 programs

  1. sotorasibphase 3
  2. afliberceptphase 3

Their studies: Amgen’s studies of Colorectal Neoplasms in search

–

Simcere Pharmaceutical Group in Colorectal Neoplasms: 4 programs

  1. suvemcitugphase 3
  2. tipiracilphase 3
  3. Trifluridinephase 3
  4. trilaciclibapproved, new study

Their studies: Simcere Pharmaceutical Group’s studies of Colorectal Neoplasms in search

Small Cell Lung Carcinoma2 of 3 · compare here

Amgen in Small Cell Lung Carcinoma: 4 programs

  1. tarlatamabphase 3
  2. etakafusp alfaphase 1
  3. tambotatug pelitecanphase 1
  4. Zocilurtatug Pelitecanphase 1

Their studies: Amgen’s studies of Small Cell Lung Carcinoma in search

–

Simcere Pharmaceutical Group in Small Cell Lung Carcinoma: 1 program

  1. trilaciclibapproved, new study

Their studies: Simcere Pharmaceutical Group’s studies of Small Cell Lung Carcinoma in search

Neoplasm Metastasis2 of 3 · compare here

Amgen in Neoplasm Metastasis: 1 program

  1. WRN Inhibitor AMG 436phase 1

Their studies: Amgen’s studies of Neoplasm Metastasis in search

Otsuka in Neoplasm Metastasis: 2 programs

  1. futibatinibphase 3
  2. zimberelimabphase 3

Their studies: Otsuka’s studies of Neoplasm Metastasis in search

–
Neoplasms2 of 3 · compare here

Amgen in Neoplasms: 2 programs

  1. tarlatamabphase 3
  2. teprotumumabapproved, new study

Their studies: Amgen’s studies of Neoplasms in search

–

Simcere Pharmaceutical Group in Neoplasms: 1 program

  1. SIM0689phase 1

Their studies: Simcere Pharmaceutical Group’s studies of Neoplasms in search

Arthritis, Rheumatoid2 of 3 · compare here

Amgen in Arthritis, Rheumatoid: 1 program

  1. dazodalibepphase 3

Their studies: Amgen’s studies of Arthritis, Rheumatoid in search

Otsuka in Arthritis, Rheumatoid: 1 program

  1. HBM7020phase 1

Their studies: Otsuka’s studies of Arthritis, Rheumatoid in search

–
Breast Neoplasms2 of 3 · compare here–

Otsuka in Breast Neoplasms: 1 program

  1. futibatinibphase 3

Their studies: Otsuka’s studies of Breast Neoplasms in search

Simcere Pharmaceutical Group in Breast Neoplasms: 1 program

  1. SIM0270phase 3

Their studies: Simcere Pharmaceutical Group’s studies of Breast Neoplasms in search

Dermatitis, Atopic2 of 3 · compare here–

Otsuka in Dermatitis, Atopic: 1 program

  1. difamilastphase 3

Their studies: Otsuka’s studies of Dermatitis, Atopic in search

Simcere Pharmaceutical Group in Dermatitis, Atopic: 1 program

  1. SIM0278phase 2

Their studies: Simcere Pharmaceutical Group’s studies of Dermatitis, Atopic in search

Lupus Erythematosus, Systemic2 of 3 · compare here

Amgen in Lupus Erythematosus, Systemic: 1 program

  1. inebilizumabapproved, new study

Their studies: Amgen’s studies of Lupus Erythematosus, Systemic in search

Otsuka in Lupus Erythematosus, Systemic: 1 program

  1. VIS171phase 1

Their studies: Otsuka’s studies of Lupus Erythematosus, Systemic in search

–
Lymphoma, B-Cell2 of 3 · compare here

Amgen in Lymphoma, B-Cell: 1 program

  1. blinatumomabapproved, new study

Their studies: Amgen’s studies of Lymphoma, B-Cell in search

Otsuka in Lymphoma, B-Cell: 1 program

  1. ARC-02phase 1

Their studies: Otsuka’s studies of Lymphoma, B-Cell in search

–

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetAmgenOtsukaSimcere Pharmaceutical Group
VEGFAafliberceptrule–suvemcitugrule, SIM0689rule
PDE4Aapremilastruledifamilastrule–
PDE4Bapremilastruledifamilastrule–
PDE4Capremilastruledifamilastrule–
PDE4Dapremilastruledifamilastrule–
A target, or a pathogen for a vaccine, known for: Amgen 17 of 24 · Otsuka 7 of 25 · Simcere Pharmaceutical Group 7 of 16 programs (29 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.